Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of LY2606368 (Prexasertib Mesylate Monohydrate) a CHK1/2 Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors

NCT02808650 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT02808650
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02808650 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of LY2606368 (Prexasertib Mesylate Monohydrate) a CHK1/2 Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Lead sponsor
Children's Oncology Group
Phase
Phase 1
Overall status
Completed
Start date
February 27, 2017
Completion date
March 31, 2021
Enrollment
30 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

childhood solid neoplasm, recurrent malignant solid neoplasm, recurrent primary central nervous system neoplasm, refractory malignant solid neoplasm, refractory primary central nervous system neoplasm